Julie Sneddon

Title: Julie Sneddon: Cancer Research and Patent Contributions.

Introduction

Julie Sneddon is an inventor associated with Palo Alto, California, and Leland Stanford Junior University. Her patent work addresses cancer biology, including tumor-associated stromal cells and gene-expression patterns that may help predict cancer progression. She is credited with 2 patents.

Latest Patents

Bone Morphogenetic Protein Antagonist and Uses Thereof. This invention concerns proteins that are differentially expressed in tumor-associated stromal cells compared with normal stromal cells. It describes using these proteins as biomolecular targets for tumor-treatment therapies and provides compounds and pharmaceutically acceptable compositions for use in the proposed methods.

Gene Expression Signature for Prediction of Human Cancer Progression. This invention describes classifying cancers by the expression of a set of genes called the core serum response (CSR), or a subset of those genes. Its methods distinguish cancers with a quiescent CSR signature from those with an induced signature. The patent description states that patients with an induced signature have a higher probability of metastasis and that classification may help inform treatment choices and dosing.

Career Highlights

Sneddon’s listed patent contributions connect molecular and gene-expression research with potential applications in cancer classification and treatment. Her work is associated with Leland Stanford Junior University.

Collaborations

Her listed coworkers include Patrick O. Brown and Hanson Zhen. These names provide context for the research network associated with her patent work.

Conclusion

Julie Sneddon’s two patents focus on potential cancer-treatment targets and gene-expression signatures that may support predictions about cancer progression and treatment decisions.